See more : China Fangda Group Co., Ltd. (200055.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of iBio, Inc. (IBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of iBio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- ASUSTeK Computer Inc. (ASUUY) Income Statement Analysis – Financial Results
- PBT Group Limited (PBG.JO) Income Statement Analysis – Financial Results
- Lion Rock Resources Inc. (KBGCF) Income Statement Analysis – Financial Results
- CSC Financial Co., Ltd. (601066.SS) Income Statement Analysis – Financial Results
- Bravo Enterprises Ltd. (OGNG) Income Statement Analysis – Financial Results
iBio, Inc. (IBIO)
About iBio, Inc.
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 225.00K | 0.00 | 2.38M | 2.37M | 1.64M | 2.02M | 444.00K | 394.00K | 948.00K | 1.85M | 205.00K | 1.01M | 1.28M | 520.08K | 0.00 | 1.18M | 987.06K | 896.27K |
| Cost of Revenue | 0.00 | 1.11M | 216.00K | 1.46M | 703.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.84K | 485.13K | 445.72K |
| Gross Profit | 225.00K | -1.11M | 2.17M | 909.00K | 935.00K | 2.02M | 444.00K | 394.00K | 948.00K | 1.85M | 205.00K | 1.01M | 1.28M | 520.08K | 0.00 | 675.77K | 501.93K | 450.55K |
| Gross Profit Ratio | 100.00% | 0.00% | 90.94% | 38.34% | 57.08% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 57.43% | 50.85% | 50.27% |
| Research & Development | 5.19M | 10.33M | 17.73M | 9.99M | 3.21M | 5.47M | 3.99M | 4.12M | 3.16M | 3.50M | -150.00K | 3.43M | 4.98M | 3.08M | 2.52M | 797.40K | 550.00K | 673.23K |
| General & Administrative | 11.67M | 19.02M | 34.13M | 22.03M | 12.43M | 12.33M | 10.69M | 10.55M | 7.69M | 5.02M | 4.20M | 4.24M | 5.62M | 7.09M | 2.07M | 1.80M | 1.82M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.67M | 19.02M | 34.13M | 22.03M | 12.43M | 12.33M | 10.69M | 10.55M | 7.69M | 5.02M | 4.20M | 4.24M | 5.62M | 7.09M | 2.07M | 1.80M | 1.82M | 1.44M |
| Other Expenses | 0.00 | 0.00 | 13.00K | 12.00K | 10.00K | 16.00K | 19.00K | 25.00K | 21.00K | 32.00K | 45.00K | 30.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.44M |
| Operating Expenses | 16.86M | 29.34M | 51.86M | 32.02M | 15.64M | 17.81M | 14.67M | 14.67M | 10.84M | 8.52M | 4.05M | 7.67M | 10.60M | 10.17M | 4.59M | 2.60M | 2.37M | 2.12M |
| Cost & Expenses | 16.86M | 29.34M | 52.07M | 33.48M | 15.64M | 17.81M | 14.67M | 14.67M | 10.84M | 8.52M | 4.05M | 7.67M | 10.60M | 10.17M | 4.59M | 3.10M | 2.85M | 2.56M |
| Interest Income | 363.00K | 130.00K | 178.00K | 140.00K | 15.00K | 75.00K | 15.00K | 39.00K | 22.00K | 9.00K | 130.00K | 9.00K | 11.67K | 12.62K | 12.73K | 20.42K | 0.00 | 0.00 |
| Interest Expense | 172.00K | 0.00 | 1.41M | 2.45M | 2.47M | 1.90M | 1.92M | 1.93M | 807.00K | 0.00 | 122.00K | 90.00K | 62.85K | 50.50K | 13.11K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.25M | 1.11M | 3.79M | 2.41M | 2.24M | 1.75M | 1.71M | 1.68M | 940.00K | 363.00K | 361.00K | 338.00K | 329.71K | 376.81K | 337.03K | 283.95K | 245.27K | 322.04K |
| EBITDA | -14.02M | -28.12M | -25.72M | -18.35M | -11.74M | -13.95M | -12.48M | -12.53M | -8.91M | -6.30M | -3.31M | -5.86M | -5.35M | -9.28M | -5.73M | -1.62M | -1.62M | -1.34M |
| EBITDA Ratio | -6,231.56% | 0.00% | -1,918.09% | -1,305.74% | -716.54% | -691.18% | -2,811.71% | -3,181.22% | -939.87% | -340.52% | -1,611.71% | -624.63% | -994.23% | -1,312.61% | 0.00% | -139.57% | -164.16% | -149.86% |
| Operating Income | -16.63M | -29.31M | -49.69M | -31.11M | -14.00M | -15.79M | -14.23M | -14.27M | -9.89M | -6.67M | -3.84M | -6.67M | -9.33M | -9.65M | -4.59M | -1.93M | -1.87M | -1.67M |
| Operating Income Ratio | -7,392.89% | 0.00% | -2,085.19% | -1,312.15% | -854.88% | -782.36% | -3,204.28% | -3,622.84% | -1,043.57% | -360.13% | -1,873.17% | -662.07% | -730.19% | -1,856.25% | 0.00% | -163.71% | -189.00% | -185.79% |
| Total Other Income/Expenses | 1.19M | 0.00 | 184.00K | 7.90M | -2.44M | -1.81M | -1.88M | -1.87M | -764.00K | 41.00K | 174.00K | 469.00K | 3.65M | -2.49M | -1.49M | 20.42K | 0.00 | 0.00 |
| Income Before Tax | -15.44M | -29.31M | -50.30M | -23.21M | -16.44M | -17.60M | -16.11M | -16.14M | -10.66M | -6.63M | -3.67M | -6.20M | -5.62M | -12.10M | -6.08M | -1.91M | -1.87M | -1.67M |
| Income Before Tax Ratio | -6,863.56% | 0.00% | -2,110.95% | -979.04% | -1,003.91% | -872.00% | -3,627.93% | -4,096.19% | -1,124.16% | -357.91% | -1,788.29% | -615.49% | -440.34% | -2,327.44% | 0.00% | -161.97% | -189.00% | -185.79% |
| Income Tax Expense | 0.00 | -1.64M | 701.00K | 46.00K | 2.47M | -4.00K | 34.00K | 347.00K | -65.00K | -9.00K | 45.00K | 120.00K | -3.65M | 2.49M | 2.40K | 1.53K | 3.71K | 851.00 |
| Net Income | -24.91M | -29.31M | -51.01M | -23.26M | -18.92M | -17.59M | -16.11M | -14.53M | -9.76M | -6.63M | -3.67M | -6.20M | -5.68M | -12.14M | -6.08M | -1.91M | -1.87M | -1.67M |
| Net Income Ratio | -11,069.78% | 0.00% | -2,140.37% | -980.98% | -1,154.76% | -871.80% | -3,627.25% | -3,688.32% | -1,029.96% | -357.91% | -1,788.29% | -615.49% | -444.35% | -2,334.73% | 0.00% | -162.10% | -189.38% | -185.88% |
| EPS | -6.50 | -47.87 | -116.97 | -59.45 | -80.53 | -70.50 | -37.87 | -40.77 | -30.15 | -23.17 | -14.56 | -31.38 | -35.92 | -98.02 | -55.65 | -23.53 | -19.92 | -17.76 |
| EPS Diluted | -6.50 | -47.87 | -116.97 | -59.45 | -80.53 | -70.50 | -37.87 | -40.77 | -30.15 | -23.17 | -14.56 | -31.38 | -35.92 | -98.02 | -55.65 | -23.53 | -19.92 | -17.76 |
| Weighted Avg Shares Out | 3.83M | 612.25K | 436.05K | 391.25K | 234.90K | 249.54K | 425.24K | 356.44K | 323.89K | 285.98K | 251.87K | 197.52K | 158.02K | 123.88K | 109.21K | 81.06K | 93.83K | 93.83K |
| Weighted Avg Shares Out (Dil) | 3.83M | 612.25K | 436.05K | 391.25K | 234.90K | 249.54K | 425.24K | 356.44K | 323.89K | 285.98K | 251.87K | 197.52K | 158.02K | 123.88K | 109.21K | 81.06K | 93.83K | 93.83K |
Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility
Hot Penny Stocks To Buy? 7 To Watch As African Variant Shakes Markets
iBio, Inc. (IBIO) CEO Thomas Isett on Q3 2021 Results - Earnings Call Transcript
iBio to Report Fiscal 2022 First Quarter Financial Results and Provide Corporate Update on Monday, November 15, 2021
Hot Penny Stocks to Watch That You Might've Missed This Week
This Under-the-Radar Pharma Company Could Be a Bargain Hunter's Dream
iBio, Inc. (IBIO) CEO Thomas Isett on Q4 Fiscal 2021 Results - Earnings Call Transcript
iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update
iBio to Participate in the Cantor 2021 Virtual Global Healthcare Conference
iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Monday, September 27, 2021
Source: https://incomestatements.info
Category: Stock Reports